bioMerieux : CMD feedback: the medium-term roadmap slightly above or at the high end of consensus forecasts
>A plan for sales growth of +7%/per annum and +10% for contributing EBIT - Yesterday, bioMérieux hosted its CMD. Management presented a road map out to 2028. In its five-year plan (Plan GO 2028) bioMérieux notably anticipates i/ sales growth of 7%/annum (2024-2028e CAGR), ii/ an operating margin of 20% in 2028 (vs 16.1% in 2024 and around 17.3%e excluding forex which is set to be unfavourable), i.e. a 340bp improvement in the operating margin between 2023 and 2028, ii...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.